Remidio MediosHI AI 3-in-1 Retinal Screening

Remidio is an AI-powered retinal imaging and oculomics company with offices in Bangalore (India), Glen Allen (Virginia, USA) and Singapore, and more than 200 employees. It makes portable and clinic fundus cameras together with screening software.

MediosHI AI 3-in-1 screens for diabetic retinopathy, glaucoma and age-related macular degeneration from a single retinal image. The AI runs fully on the device without internet, integrated into the Insta FOP NM 10 handheld non-mydriatic camera, and was prospectively validated across 20+ clinical sites per the vendor. Remidio cites 4,000 devices and use in 55+ countries.

• Three-disease AI: Screens DR, glaucoma and AMD from one retinal image.
• On-device inference: Runs offline inside the Insta FOP NM 10 handheld camera.
• Non-mydriatic imaging: Captures wide-field images without dilation or high-intensity flash.
• Remidio Connect: Telemedicine platform for sharing images with doctors.
• Oculomics: Retinal biomarkers for cardiovascular and kidney risk assessment.

Provincial endocrinology centers in Vietnam can screen diabetic patients with a handheld camera. Mobile eye-care outreach teams can screen rural communities offline. Health-check chains can add retinal AI to annual packages.

Offline, on-device AI works in outreach camps and clinics without connectivity.

One image screens three leading causes of preventable blindness.

Handheld camera captures images without dilation drops, lowering screening effort.

Reported scale of 16M+ patients screened and 4,000 devices worldwide (vendor figures).

Diabetes prevalence in Vietnam and Southeast Asia is rising while ophthalmologists are concentrated in cities, so portable offline screening suits community and primary-care programs. Retinal imaging is also being explored for systemic disease risk.

Offices in Bangalore (India), Glen Allen (USA) and Singapore (Medios Technologies). CEO and Founding Director Dr Anand Sivaraman. 35+ patents filed and 90+ publications per the site. Gates Foundation grant for maternal health use reported 10 June 2026. Visionix partnership for an imaging module.